RUSSELL DOXEY: Open Payments
NPI 1770161473 · ROY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$509 in 30 payments from 16 companies in 2025. Trend: 2023 $317 · 2024 $489 · 2025 $509
Food & beverage: $509
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $73 |
| PFIZER INC. | 3 | $60 |
| Lilly USA, LLC | 4 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Seqirus USA Inc | 1 | $23 |
| SANOFI-AVENTIS U.S. LLC | 1 | $22 |
| Cranial Technologies, Inc | 1 | $20 |
Products named: TRELEGY ELLIPTA, MOUNJARO, CAPLYTA, NURTEC ODT, SPRAVATO, XIFAXAN, Fluad, PROQUAD.
Industry payments across UT — which companies pay providers there.
